BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32650968)

  • 1. [Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    López-Ríos F; Paz-Ares L; Sanz J; Isla D; Pijuan L; Felip E; Gómez-Román JJ; de Castro J; Conde E; Garrido P
    Rev Esp Patol; 2020; 53(3):167-181. PubMed ID: 32650968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    Garrido P; Conde E; de Castro J; Gómez-Román JJ; Felip E; Pijuan L; Isla D; Sanz J; Paz-Ares L; López-Ríos F
    Clin Transl Oncol; 2020 Jul; 22(7):989-1003. PubMed ID: 31598903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Belén Enguita A
    Rev Esp Patol; 2023; 56(2):97-112. PubMed ID: 37061248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive markers in lung cancer: a few hints for the practicing pathologist.
    Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
    Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Enguita AB
    Clin Transl Oncol; 2023 May; 25(5):1252-1267. PubMed ID: 36571695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP).
    Martín-López J; Rojo F; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; de Alda LR; García JF; Salas C
    J Clin Pathol; 2023 May; 76(5):327-332. PubMed ID: 34903610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Update of the recommendations for the determination of biomarkers in colorectal carcinoma. National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology].
    Navarro S; Cuatrecasas M; Hernández-Losa J; Landolfi S; Musulén E; Ramón Y Cajal S; García-Carbonero R; García-Foncillas J; Pérez-Segura P; Salazar R; Vera R; García-Alfonso P
    Rev Esp Patol; 2021; 54(1):41-54. PubMed ID: 33455693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).
    Salas C; Martín-López J; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; Ruiz de Alda L; García JF; Rojo F
    J Clin Pathol; 2022 Mar; 75(3):193-200. PubMed ID: 33722840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
    Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
    Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
    Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
    Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
    Garrido P; de Castro J; Concha Á; Felip E; Isla D; López-Ríos F; Paz-Ares L; Ramírez J; Sanz J; Gómez JJ
    Clin Transl Oncol; 2012 May; 14(5):338-49. PubMed ID: 22551539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
    Ekin Z; Nart D; Savaş P; Veral A
    Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic mutations and immune checkpoint biomarkers.
    Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA
    Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
    Cagle PT; Raparia K; Portier BP
    Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.
    Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
    Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
    Benjamin DJ; Haslam A; Gill J; Prasad V
    Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
    Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
    Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.